Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Andrew L. Faber"'
Autor:
Lillian Sams, Sandaruwan Geeganage, Michael Kalos, Andrew L. Faber, Frank C. Dorsey, Daniel Jon Sall, David K. Clawson, John F. Schindler, William T. McMillen, Zhao Gaiying, Bonita D. Jones, Karim A. Benhadji, Debra A. Young, Carmine Carpenito, Henry James Robert, James E. Thomas, Steven Haney, Tod Smeal, Karen L. Huss, Alexander Nikolayev
Publikováno v:
Cancer Research. 78:5245-5245
Indoleamine 2,3-dioxygenase 1 (IDO1) is a heme-dependent enzyme that catalyzes the initial and rate-limiting step of tryptophan catabolism resulting in the local depletion of tryptophan and the concomitant production of kynurenine, both of which are
Publikováno v:
Molecular cancer therapeutics. 6(9)
Thrombin cleavages of selective proteinase-activated receptors (PAR) as well as PAR-activating peptide ligands can initiate the phosphoinositide 3-kinase (PI3K) signaling cascade in platelets. Downstream to this event, fibrinogen receptors on platele
Autor:
Christiane M. Robbins, Mark Uhlik, Jeffrey W. Touchman, Andrew L. Faber, Mei-Huei T. Lai, Stephanie Savage, Aimin Lin, Galen Hostetter, Jian Du, Yue-Wei Qian, Gregory P. Donoho, Tracy Moses, Michael L. Bittner, Kerry L. Blanchard, Spyro Mousses, Stephen L. Briggs, Douglas J. Zeckner, Sophie Boguslawski, Candice Horn, Greg Tucker-Kellogg, Ketan J. Patel, James E. Thomas, Richard W. Schevitz, John D. Carpten
Publikováno v:
Nature. 448(7152)
Although AKT1 (v-akt murine thymoma viral oncogene homologue 1) kinase is a central member of possibly the most frequently activated proliferation and survival pathway in cancer, mutation of AKT1 has not been widely reported. Here we report the ident
Autor:
Andrew L. Faber, Cliffton T. H. Bong, Stanley M. Spinola, Barry P. Katz, Stacy L. Bennett, Carisa A. Townsend, Steven D. Billings, Tricia L. Humphreys, Beth Zwickl, Kate R. Fortney, Margaret E. Bauer
Publikováno v:
Infection and immunity. 71(11)
With human volunteers inoculated at two sites withHaemophilus ducreyi, outcomes for a subject were not independent. In a reinfection trial, 2 of 11 previous pustule formers and 6 of 10 previous resolvers resolved all sites of infection. There was no
Publikováno v:
Cancer Research. 72:5595-5595
The clinical success of crizotinib against mutant ALK-expressing cancers has generated great interest; however, the emergence of drug resistance is limiting its durability in some patients. In NSCLC, crizotinib resistance is linked to secondary mutat
Autor:
Andrew L. Faber
Publikováno v:
Stanford Law Review. 26:131